AnalystsMaxwell SkorMaxwell Skor's Stock Forecasts
AnalystsMaxwell Skor
Sectors:
Industries:
Analyst Ranking
Top 30%
#1636 out of 5550 analysts
Average Return
+24.63%
Win Rate
50%6 out of 12
Risk vs Reward
Poor
Good
Maxwell Skor's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Invivyd IncIVVD | +225.52% | $0.77 | $2.50 | 2024-11-20 - 2025-11-19 | Strong Buy |
Cidara Therapeutics IncCDTX | +117.00% | $102.02 | $221.38 | 2025-10-16 - 2026-01-06 | Strong Buy |
Ascendis Pharma AASND | +57.60% | $174.18 | $274.50 | 2025-07-03 - 2026-07-02 | Strong Buy |
Sana Biotechnology IncSANA | +25.71% | $3.19 | $4.01 | 2025-07-03 - 2026-07-02 | Strong Buy |
Monopar TherapeuticsMNPR | +11.62% | $63.00 | $70.32 | 2026-01-09 - 2026-10-30 | Strong Buy |
Maxwell Skor Analyst Color
Get additional color on Maxwell Skor's coverage of popular stocks
Maxwell Skor's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Ultragenyx Pharmaceutical IncRARE | 1 | Hold | $20.00 | +24.22% | Maintains | a month ago |
Pharvaris NvPHVS | 2 | Strong Buy | $62.00 | +84.91% | Maintains | 2 months ago |
Ascendis Pharma AASND | 3 | Strong Buy | $273.00 | +8.65% | Maintains | 2 months ago |
Achieve Life Sciences IncACHV | 1 | Strong Buy | $13.00 | +90.34% | Initiates Coverage On | 3 months ago |
Monopar TherapeuticsMNPR | 1 | Strong Buy | $115.00 | +63.54% | Initiates Coverage On | 10 months ago |
Cidara Therapeutics IncCDTX | 1 | Strong Buy | $190.00 | N/A | Initiates Coverage On | a year ago |
Insmed IncINSM | 1 | Hold | $144.00 | N/A | Maintains | a year ago |
Sana Biotechnology IncSANA | 1 | Strong Buy | $12.00 | N/A | Assumes | a year ago |
Tscan Therapeutics IncTCRX | 1 | Strong Buy | $10.00 | N/A | Assumes | 2 years ago |
Invivyd IncIVVD | 2 | Strong Buy | $3.55 | N/A | Maintains | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.